BIO 2026: How NIH cuts have threatened US competitiveness against China

Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors. Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors. Stakeholders across US biopharma expressed concern that cuts to NIH funding risked the nation’s world-leading position in biomedical research. Credit: Rena Schild/Shutterstock.com Funding cuts at US federal agencies have compounded threats to the US’s predominance in global biopharma as an ascendant Chinese industry looks to turn local biotech innovation into pharma companies with a global reach. This was…

Source: Clinical Trials Arena